Inspira Technologies (NASDAQ:IINN) has announced its preparations for a possible increase in production of its INSPIRA ART100 device to address the growing demand for advanced respiratory care technologies following the recent outbreak of human metapneumovirus (hMPV) in China.
The company stated that it is implementing precautionary measures aligned with its commitment to global health readiness. Accordingly, Inspira is engaging with leading providers in the affected regions to evaluate demand and with suppliers to secure raw materials and components.
In a statement, Dagi Ben-Noon, CEO of Inspira, said, “While hMPV is not a new virus, and experts indicate the current outbreak is part of normal seasonal patterns, Inspira believes in being prepared. Our increased production capacity will help ensure healthcare providers have access to vital respiratory care equipment should the need arise.”
